Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan (S.K., N.S., G.T., T.Y.).
Department of Pharmacology, Faculty of Medicine, Kagawa University, Japan (S.K., A.N.).
Hypertension. 2021 Jan;77(1):16-27. doi: 10.1161/HYPERTENSIONAHA.120.16044. Epub 2020 Nov 23.
Owing to aging populations, the prevalence of hypertension and associated cardiovascular events has been increasing worldwide. The morbidity and mortality due to cancer have also been increasing with aging populations. Several small-molecule inhibitors have been used in cancer therapy, which have a positive impact on the prognosis and survival of patients with cancer. Consequently, the number of cancer survivors with hypertension has been rapidly increasing. Anticancer therapy, including vascular endothelial growth factor inhibitors, increases blood pressure. However, both clinical and laboratory evidence are lacking regarding optimal blood pressure control in patients with hypertension with cancer. Here, we propose the concept of onco-hypertension, which is an evolving subspecialty focused on the complex pathophysiology of hypertension and cancer. In this review, we highlight blood pressure changes in cancer, hypertension induced by anticancer therapy, and optimal blood pressure management in patients with hypertension with cancer. In addition, we discuss needed studies to further establish this new onco-hypertension concept.
由于人口老龄化，高血压的患病率以及与之相关的心血管事件在全球范围内呈上升趋势。随着人口老龄化，癌症的发病率和死亡率也在增加。一些小分子抑制剂已被用于癌症治疗，这对癌症患者的预后和生存有积极影响。因此，高血压合并癌症的幸存者人数迅速增加。癌症治疗，包括血管内皮生长因子抑制剂，会导致血压升高。然而，临床和实验室证据均缺乏高血压合并癌症患者的最佳血压控制标准。在这里，我们提出了肿瘤相关性高血压的概念，这是一个专注于高血压和癌症复杂病理生理学的新兴亚专科。在这篇综述中，我们重点介绍了癌症患者的血压变化、抗癌治疗引起的高血压以及高血压合并癌症患者的最佳血压管理。此外，我们还讨论了需要进一步建立这一新的肿瘤相关性高血压概念的研究。
